[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aesculap AG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":490},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,41,67,100,125,152,177,199,226,258,283,312,336,359,388,414,443,467],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100603165","leakage-rate-of-ileo-colic-sutured-anastomosis-after-right-hemicolectomy-100603165",false,"NCT07132970","Leakage Rate of Ileo-COlic Sutured Anastomosis After Right Hemicolectomy","Assessment of the Leakage Rate of Ileo-colic Sutured Anastomoses Using a Polydioxanone Based Suture Material After Laparoscopic or Open Right Hemicolectomy to Treat Malignancy","LICOSARH","Inclusion Criteria:\n\n* Patients undergoing a primary, elective either open or laparoscopic right hemicolectomy or right extended hemicolectomy due to malignancy with the creation of an intracorporeal or extracorporeal ileo-colic anastomosis.\n* Either complete hand-sewn anastomosis or partial sutured anastomosis (e.g. combination of stapling and suturing)\n* Open or laparoscopic as well as conversion from open to laparoscopic surgery\n* Absence of peritoneal carcinomatosis\n* Absence of vascular, nervous or bone infiltration\n* Age ≥ 18 years\n* Written data protection declaration (Written Informed consent)\n\nExclusion Criteria:\n\n* Left hemicolectomy or left extended hemicolectomy or sigma resection\n* Inflammatory bowel disease (e.g. Crohn´s disease)\n* Emergency surgery\n* Previous abdominal surgery with bowel resection\n* Re-operation of an anastomosis (anastomosis revision surgery)\n* Need for stoma creation\n* Non-compliant patients\n* Participation in an interventional randomized controlled study (RCT)","ALL","18 Years",{"count":20,"type":21},249,"ESTIMATED","OBSERVATIONAL","The primary aim of the study is to show that the ileo-colic anastomosis leakage rate until the first 30 days after surgery using MonoPlus® suture material for anastomosis construction after right hemicolectomy is not inferior to the anastomosis leakage rate published in the literature for totally handsewn or stapled-handsewn ileo-colic anastomosis.",[25,26,27],"Anastomotic Leak","Colon Cancer","Right Hemicolectomy","RECRUITING","2026-06-08",{"date":31,"type":32},"2026-06-09","ACTUAL",{"date":34,"type":32},"2026-01-26",{"date":36,"type":21},"2028-03",{"name":38,"class":39},"Aesculap AG","INDUSTRY",4,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100558132","pilot-study-on-the-effectiveness-and-safety-of-optilene-silver-mesh-elastic-in-prevention-of-surgical-site-infection-ssi-and-incisional-hernia-ih-100558132","NCT06547138","Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)","Prospective Descriptive Multicentre Pilot Study On The Effectiveness and Safety Of Optilene® Silver Mesh Elastic In Prevention Of Surgical Site Infection (SSI) And Incisional Hernia (IH)","SSIHLVER","Inclusion Criteria:\n\n* Adult patients (18 years or older)\n* Surgical procedure requiring urgent, primary median laparotomy, which are classified as \"Class III\u002FContaminated\" or \"Class IV\u002FDirty-Infected\" regarding the CDC classification.\n\nThese include but are not limited to:\n\n* Vascular surgery\n* Colon and rectum\n* Hepatobiliary\n* Gastrointestinal\n* Gynecology\n* Urology\n* Abdominal Aortic Aneurysm (AAA) repair\n* Right hemicolectomy\n* Left hemicolectomy\n* Sigmoidectomy\n* Anterior resection\n* Abdominoperineal amputation\n* Exploratory laparotomy\n* Cholecystectomy\n* Cholecystectomy and choledocotomy\n\n  * Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Breast feeding\n* Patients \\\u003C 18 years old or patients who are still in the growth phase\n* Contaminated and infected areas\n* Hypersensitivity to silver\n* Direct contact with the viscera\n* Previous allergic reactions to components of the device\n* Patient with previous laparotomy\n* Transverse laparotomy\n* Patients with previous hernia repair\n* Simultaneous participation in another investigational clinical trial (drug or medical studies)\n* Patients with active oncologic treatment (chemo and radiotherapy)\n* Underlying autoimmune disease\n* Recent cardiovascular complication\n* Gynecology surgery\n* Urology surgery\n* Vascular surgery",{"count":50,"type":21},110,"The aim of the study is to describe the effectiveness of Optilene® Silver Mesh Elastic on prevention of surgical site infection (SSI) at 6 months follow-up in patients undergoing urgent laparotomy by collecting clinical data on the SSI rates, IH rates and overall clinical performance of Optilene® Silver Mesh Elastic used for the prevention of incisional hernia as prophylactic mesh in patients that require urgent median laparotomy in clinical routine.",[53,54],"Abdominal Aortic Aneurysm","Morbid Obesity",[56],"urgent, primary median laparotomy","NOT_YET_RECRUITING","2026-06-01",{"date":60,"type":32},"2026-06-02",{"date":62,"type":21},"2026-09",{"date":64,"type":21},"2028-09",{"name":38,"class":39},5,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":75,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":88,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100517943","performance-of-symmcora-vs-v-loc-suture-material-in-patients-undergoing-laparoscopic-total-hysterectomy-100517943","NCT06024109","Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy","Prospective, International, Randomized, Multicentric, Controlled Study on the Performance of SYMMCORA® Mid-term Unidirectional Barbed Suture Versus V-loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy","BARHYSTER","Inclusion Criteria:\n\n* Females undergoing an elective, laparoscopic total hysterectomy\n* Age ≥ 18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* Emergency surgery\n* Open surgery\n* Patients undergone immunosuppressive drug treatment within the prior 6 months\n* Patients with hypersensitivity or allergy to the suture material.\n* Participation in another clinical study\n* Non-compliance of patient","FEMALE",{"count":77,"type":21},132,"The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate.\n\nSecondly, the superiority of SYMMCORA®, mid-term unidirectional compared to the V-Loc®, unidirectional will be assessed regarding the mean time to close the vaginal cuff. The study will be performed in routine clinical setting, the only difference will be the randomization into two different suture groups. Both suture materials which will be applied to approximate the vaginal cuff are approved and carrying the CE-marks. Additionally, both sutures will be applied in their intended use. Neither additional invasive measures nor additional burden in regard to the patient will be performed.",[80,81,82,83,84,85,86,87],"Abnormal Uterine Bleeding","Endometriosis","Uterine Prolapse","Uterine Cancer","Ovarian Cancer","Fallopian Tube Cancer","Cervical Cancer","Endometrial Cancer",[89,90,91,92],"Barbed Suture","Hysterectomy","Laparoscopy","Minimal Invasive",{"date":60,"type":32},{"date":95,"type":32},"2024-03-19",{"date":97,"type":21},"2027-08",{"name":38,"class":39},2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":110,"conditions":111,"keywords":117,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":99},"100460909","post-market-clinical-follow-up-study-on-the-safety-and-performance-of-ennovate-complex-100460909","NCT05281757","Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Complex","Multicenter Post Market Clinical Follow-Up (PMCF) Study on the Safety and Performance of Ennovate® Complex - A Prospective Study on Scoliosis Patients","COSINE","Inclusion Criteria:\n\n* Informed consent in the documentation of clinical and radiological results of patients who are minimum 18 years old\n* Informed consent in the documentation of clinical and radiological results of patients AND legal representative (parent) for patients who are younger than 18\n* Patient's indication according to IFU\n* Patient is not pregnant\n\nExclusion Criteria:\n\n* Patient's clear unability or unwillingness to participate in follow-up examinations",{"count":109,"type":21},200,"Multicenter, multinational Post-Market Clinical Follow-Up (PMCF) study on the safety and performance of Ennovate® Complex - A prospective, pure data collection of all Ennovate® scoliosis patients in selected centers (not interventional, multicentric)",[112,113,114,115,116],"Hyperkyphosis","Hyperlordosis","Congenital Scoliosis","Neuromuscular Scoliosis","Idiopathic Scoliosis",[118],"upper-thoracic spine",{"date":60,"type":32},{"date":121,"type":32},"2022-02-18",{"date":123,"type":21},"2028-10",{"name":38,"class":39},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":40},"100566597","clinical-performance-and-safety-of-the-unicompartmental-univation-xf-pro-implant-100566597","NCT06657248","Clinical Performance and Safety of the Unicompartmental Univation® XF Pro Implant","Prospective, Multicenter Study Evaluating the Midterm Clinical Performance and Safety of the Unicompartmental Univation® XF Pro Knee Implant","UNI_XF_PRO","Inclusion Criteria:\n\n* Indication for a primary medial unicompartmental knee endoprosthesis\n\nAcc. to Instructions for Use:\n\n* Both cruciate ligaments intact\n* Lateral ligaments intact\n* Leg axis amenable to passive correction\n* Varus deformity under 15°\n* Bending capability of at least 90°\n* Extension deficit no greater than 5-10°\n* Written informed consent of patient\n* Kellgran \\& Lawrence Score \\> II (only straight or varus\n* Patients with moderate radiological symptoms\n* Patients without clinical symptoms\n\nExclusion Criteria:\n\n* Pregnancy\n* Patient age \\\u003C18 and \\> 75 years\n* BMI ≥ 40\n* High risk patients ASA \\> III","75 Years",{"count":135,"type":21},150,"The study is designed as a prospective, observational, mid-term, multi-center follow-up study. It is planned to include 150 patients from 4 different study centres in Germany.",[138,139],"Gonarthritis","Degenerative Disease",[141,142,143],"Degenerative medial unicompartmental Gonarthrosis","Unicompartmental knee arthroplasty","Safety and Performance","2026-05-05",{"date":146,"type":32},"2026-05-08",{"date":148,"type":32},"2026-04-02",{"date":150,"type":21},"2032-10",{"name":38,"class":39},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":99},"100564231","prospective-follow-up-of-the-prevision-hip-stem-with-comparison-of-different-implant-variants-100564231","NCT06626490","Prospective Follow-up of the Prevision Hip Stem With Comparison of Different Implant Variants","PREMO","Inclusion Criteria:\n\n* Revision hip arthroplasty patients treated with a Prevision hip stem\n* Written patient informed consent\n* Patients are able to attend at follow-up examinations\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years at surgery\n* Pregnancy at implantation\n* Patients held in a custodial setting\n* Patients in a relationship of dependence on the sponsor, the clinic or the investigator",{"count":160,"type":21},120,"The study design is confirmative for non-inferiority of the functional outcome of the implants and is intended to examine the safety and performance of the Prevision hip stem. The study is an observational post-market clinical follow-up study, and the study sites chose the stem variant depending on their own routine and indication.",[163,164],"Revision Total Hip Arthroplasty","Periprosthetic Fracture of Hip",[166,167,168],"Patient-reported outcomes","Clinical performance and safety","Total hip arthroplasty implantation","2026-04-30",{"date":171,"type":32},"2026-05-01",{"date":173,"type":32},"2026-04-07",{"date":175,"type":21},"2034-03",{"name":38,"class":39},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":197,"locationsCount":198},"100612783","study-on-histoacryl-used-for-embolization-of-middle-meningeal-artery-mma-in-chronic-subdural-hematoma-csdh-harmony-100612783","NCT07258069","Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH) (HARMONY)","Observational, Prospective, Multicenter Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH) (HARMONY)","HARMONY","Inclusion Criteria:\n\n* 18 years old or older\n* Confirmed diagnosis of chronic subdural hematoma (CSDH) or recurrent subdural hematoma (SDH)\n* Completed documented informed consent\n* Willingness and presumed capability to participate in follow-up visits for up to 6 months (180±30 days)\n\nExclusion Criteria:\n\n* Extensive cerebral infarction, brain tumor, or space-occupying lesion requiring treatment\n* Need craniotomy\n* Any sign of anatomical variations that could make MMA embolization unsafe (e.g., prominent MMA-opthalmic artery anastomoses)\n* Coagulation dysfunction with INR\\>1.8 and\u002For platelet count \\\u003C80x109 \u002FL\n* Allergic reactions to essential medicines to do angiography\n* Women who are pregnant, lactating, or who are of childbearing age and plan on becoming pregnant during the study\n* Participation in another clinical trial",{"count":186,"type":21},178,"The aim of the study is to proof the effectiveness of Histoacryl® on preventing recurrence or progression of subdural hematoma after embolization of the middle meningeal artery.",[189,190],"Subdural Hematoma","Subdural Hematoma, Chronic","2026-04-15",{"date":193,"type":32},"2026-04-17",{"date":195,"type":32},"2026-04-10",{"date":97,"type":21},{"name":38,"class":39},7,{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":209,"phases":210,"briefSummary":212,"conditions":213,"keywords":216,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":225},"100589869","clinical-study-on-the-safety-and-efficacy-of-the-minimally-invasive-ennovate-method-for-pedicle-screw-placement-100589869","NCT06960018","Clinical Study on the Safety and Efficacy of the Minimally Invasive Ennovate® Method for Pedicle Screw Placement","Controlled, Randomized Clinical Study to Demonstrate the Patient Benefit and Safety of Pedicle Screw Placement Through an Innovative Minimally Invasive Surgical Approach Using the Ennovate® Cervical Spinal System","MISPEC","Inclusion Criteria:\n\n* All patients with minimum 18 years of age receiving Ennovate® Cervical internal fixation device within the vertebral bodies C2-Th3 to ensure the restoration and stabilization of the cervical spine\n\nExclusion Criteria:\n\n* All patients not willing to sign the patient consent are excluded. Also, if it is clear from the beginning, that the patient will not be able to come to routine follow-up, the patient will also be excluded.\n\nAbsolute contraindications according to the IFU:\n\n* Severe damage to the bone structures of the spine that could prevent the stable implantation of the implant components; for example, osteopenia, severe osteoporosis, Paget's disease, bone tumors etc.\n* Metabolic or degenerative metabolic bone diseases that could compromise the stable anchoring of the implant system.\n* Suspected allergy or sensitivity to the implant materials.\n* Acute or chronic vertebral infections of a local or systemic nature.\n* Poor patient compliance or limited ability to follow medical instructions, particularly in the postop phase, including with regard to the restrictions on range of movement in terms of physical exercise and occupational activity.",{"count":208,"type":21},76,"INTERVENTIONAL",[211],"NA","The study's main purpose is the collection of clinical data on the patients benefit and safety of pedicle screw placement through an innovative minimally invasive surgical approach compared to the state of the art open surgical approach using the Ennovate® Cervical Spinal System.",[214,215],"Cervical Spine Disease","Pain, Postoperative",[217,218],"posterior cervical fusion","pedicle screw",{"date":191,"type":32},{"date":221,"type":32},"2025-06-20",{"date":223,"type":21},"2028-11",{"name":38,"class":39},3,{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":237,"conditions":238,"keywords":243,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":257},"100514587","comparative-study-of-navigation-assisted-orthopilot-elite-and-robotic-assisted-mako-total-knee-arthroplasty-100514587","NCT05980442","Comparative Study of Navigation-assisted OrthoPilot® Elite and Robotic-assisted MAKO® Total Knee Arthroplasty","Randomized, Controlled, Single Center Observational Study to Compare the Safety and Performance of Navigation-assisted OrthoPilot® Elite and Robotic-assisted MAKO® Total Knee Arthroplasty","ORMAK","Inclusion Criteria:\n\n* Indication for a TKA with a fixed-bearing total knee endoprosthesis\n* Written informed consent for participating in the clinical study\n\nExclusion Criteria:\n\n* Patient age \\\u003C18 years and \\>90 years\n* Patient not willing to participate at the follow-up\n* Pregnancy\n* retropatellar arthrosis requiring patella resurfacing\n* American Society of Anaesthesiologists (ASA) Classification \\>3","90 Years",{"count":236,"type":21},140,"Randomized, controlled, single center observational study to compare the safety and performance of navigation-assisted OrthoPilot Elite and robotic-assisted MAKO total knee arthroplasty (TKA). The aim of the study is the comparison of the clinical outcome between navigated and robotic-assisted TKA. The hypothesis of the study is that both treatments achieve similar results regarding functional and clinical aspects.",[239,240,241,242],"Osteoarthritis, Knee","Joint Diseases","Rheumatoid Arthritis of Knee","Posttraumatic Arthropathy",[244,245,246,247,248],"computer assisted orthopedic surgery","robotic assisted orthopedic surgery","orthopedic navigation","total knee arthroplasty","total knee replacement","2026-03-26",{"date":251,"type":32},"2026-03-27",{"date":253,"type":32},"2024-07-03",{"date":255,"type":21},"2028-12",{"name":38,"class":39},1,{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":267,"conditions":268,"keywords":274,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":40},"100462071","post-market-clinical-follow-up-study-on-the-safety-and-performance-of-ennovate-cervical-100462071","NCT05296889","Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical","Multicenter Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Cervical - a Prospective Study on Total Indications","CERISE","Inclusion Criteria:\n\n* Patient is minimum 18 years old\n* Informed Consent in the documentation of clinical and radiological results\n* Patient has indication according to Instructions for Use (IFU)\n* Patient is not pregnant\n\nExclusion Criteria:\n\n* Patient's clear unability or unwillingness to participate in follow-up examinations",{"count":109,"type":21},"Multicenter Post market clinical follow-up Study on the Safety and Performance of Ennovate® Cervical - Prospective, pure data collection of all Ennovate Cervical patients in Total Indications",[269,270,271,272,273],"Spine Fracture","Degenerative Disc Disease","Spinal Instability","Spinal Tumor","Degenerative Myelopathy",[275],"Cervical Spine",{"date":277,"type":32},"2026-03-31",{"date":279,"type":32},"2021-07-21",{"date":281,"type":21},"2026-07",{"name":38,"class":39},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":291,"targetDuration":293,"studyType":22,"phases":4,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":311,"locationsCount":40},"100513553","novosyn-chd-vs-polyglactin-910-suture-to-close-wounds-after-emergency-or-elective-laparotomy-or-laparoscopic-surgery-100513553","NCT05966961","Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery","'All Comer'\u002F'Real-world' Registry-based Randomized, Prospective, Multicenter Clinical Trial to Evaluate the Incidence of Complications Using Novosyn® CHD Suture Versus Polyglactin 910 Suture to Close the Wound After Emergency or Elective Laparotomy or Laparoscopic Surgery","POLYNOVO-CHD","Inclusion Criteria:\n\n* Patients undergoing an emergency or elective laparotomy or laparoscopic surgery.\n* Written informed consent\n* Age≥ 18 years\n* Not incapacitated patient\n\nExclusion Criteria:\n\n* No exclusion criteria except patients with allergy or hypersensitivity to chlorhexidine",{"count":292,"type":21},2998,"30 Days","The aim of the study is to elucidate, if the colonization of bacteria is lower on the Novosyn® CHD suture compared to uncoated Polyglactin 910 suture, which will be assessed by the incidence of surgical site infections (SSI: A1 and A2). The results of this registry will generate further clinical evidence for the use and the benefit of a Chlorhexidine coated suture used to close the wound after an emergency or elective laparoscopic or laparotomy surgery. The benefit for individual patients lies in the early diagnosis of complications and in the optimized postoperative controls of a clinical study.",[296],"Surgical Site Infection",[298,299,300,301,302,303,304],"Chlorhexidine coated suture","emergency laparoscopic surgery","emergency laparotomy surgery","elective laparoscopic surgery","elective laparotomy surgery","Novosyn®","Polyglactin 910","2026-03-05",{"date":307,"type":32},"2026-03-06",{"date":309,"type":32},"2023-09-18",{"date":255,"type":21},{"name":38,"class":39},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":209,"phases":322,"briefSummary":323,"conditions":324,"keywords":328,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":257},"100501744","novosyn-quick-versus-monosyn-quick-suture-material-in-resective-periodontal-surgery-100501744","NCT05813236","NOVOSYN® Quick Versus MONOSYN® Quick Suture Material in Resective Periodontal Surgery","Randomized, Monocentric, Double Blinded, Prospective Study to Evaluate the Early Wound Healing After the Utilization of NOVOSYN® Quick Versus MONOSYN® Quick Suture Material in Resective Periodontal Surgery","NOQMOQS","Inclusion Criteria:\n\n* Adult patient undergoing resective periodontal surgery abd one of the incisions below has been performed:\n* Crestal incision\n* Vertical incision\n* Intrasulcular incision\n* Submarginal incision\n* Written informed consent regarding the data collection for the RCT\n\nExclusion Criteria:\n\n* Emergency surgery.\n* Pregnancy.\n* Breastfeeding\n* Patients taking medication that might affect wound healing.\n* Patients having a condition that might affect wound healing.\n* Patients with hypersensitivity or allergy to the suture material",{"count":321,"type":21},84,[211],"The aim of this study is to prove that Novosyn Quick and Monosyn Quick are equivalent in early wound healing in adult patients undergoing resective periodontal surgery.\n\nIn order to show equivalence between Novosyn Quick and Monosyn Quick EHS, which is composed of 3 parameters: clinical signs of reepithelization, clinical signs of haemostasis and clinical signs of inflammation, will be calculated for each suture 10 ± 5 days postoperatively and cannot differ more than 2 points.\n\nFurthermore, complications, the handling of the suture material, pain, satisfaction of the patient and bacterial contamination of the thread (optional) will also be assessed as secondary objectives.",[325,326,327],"Gingivitis","Gingival Diseases","Periodontal Diseases",[329],"Resective periodontal surgery",{"date":307,"type":32},{"date":332,"type":32},"2023-06-28",{"date":334,"type":21},"2026-12",{"name":38,"class":39},{"id":337,"slug":338,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":209,"phases":346,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":358,"locationsCount":99},"100572353","performance-and-safety-of-lyoplant-in-guided-bone-regeneration-gbr-in-oral-surgery-100572353","NCT06732167","Performance and Safety of Lyoplant® in Guided Bone Regeneration (GBR) in Oral Surgery","Prospective, Randomized, Controlled, Multicenter Study on the Performance and Safety of Lyoplant® in Guided Bone Regeneration (GBR) in Oral Surgery","LyOral","Inclusion Criteria:\n\n* Patients who are willing to give a voluntary consent to participate in the study, following a full explanation of the nature and purpose of the study, by signing the Informed Consent Form (ICF).\n* Patients with the capacity to consent for themselves.\n* Patients in need of an implant with a simultaneous GBR procedure.\n* Presence of buccal bony dehiscence with a vertical defect height (VDH) ≥ 1 mm and ≤ 6 mm after implant placing.\n* The tooth at the implant site must have been extracted or lost at least 8 weeks before the date of bone augmentation (volumetrically healed site).\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years.\n* Currently pregnant or breastfeeding women.\n* Major systemic diseases (e.g. recent myocardial infarction, cerebrovascular accident or valvular prosthesis surgery, a poorly stabilized diabetes mellitus, severe hypertension, severe peripheral artery occlusive disease, malignancies, autoimmune diseases, or kidney diseases, untreated or uncontrolled periodontal disease, uncontrolled drug or alcohol abuse, uncontrolled psychiatric disorders).\n* Acute infectious diseases.\n* Immunocompromised patients.\n* Serious disturbances of bone metabolism and\u002For serious bone diseases of endocrine etiology.\n* Medical conditions requiring prolonged use (\\> 6 months) of steroids and\u002For ongoing treatment with gluco- and mineralocorticoids and with agents affecting calcium metabolism (e.g. calcitonin), and\u002For anticoagulative therapy.\n* Previous or current use of antiresorptive drugs (ARDs) (e.g. bisphosphonates, selective estrogen receptor modulators (SERMs), denosumab, hormone replacement therapy and calcitonin).\n* Previous oral \u002F maxillofacial radiotherapy.\n* Heavy smoker (\\>10 cigarettes\u002Fday). In the case of vapors with nicotine, the use of \\>300 puff vapors (equivalent to 10 cigarettes\u002Fday) are not allowed.\n* Health conditions, which do not permit the surgical treatment.\n* Use of the Investigational Device \u002F Comparator in infected areas.\n* Known foreign body sensitivity to implant materials.\n* Simultaneous participation in another interventional clinical trial (drugs or medical devices studies) if it could impact the result of the study.",{"count":345,"type":21},68,[211],"Guided Bone Regeneration (GBR) is a well-established surgical technique that employs barrier membranes to ensure the stability of bone augmentation material while preventing the infiltration of soft tissue, thereby facilitating new bone formation.\n\nThe primary objective of this randomized controlled trial is to assess the performance and safety of the Lyoplant® collagen membrane as a barrier membrane in GBR for patients undergoing dental implant surgery. Additionally, the study aims to compare the Lyoplant® membrane with the Bio-Gide® collagen membrane, with the goal of demonstrating the non-inferiority of the Lyoplant® membrane in terms of radiographically measured bone gain compared to the comparator.",[349],"Bone Regeneration",[351],"collagen barrier membrane","2026-02-24",{"date":354,"type":32},"2026-02-27",{"date":356,"type":32},"2025-01-24",{"date":334,"type":21},{"name":38,"class":39},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":17,"minAge":367,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":209,"phases":371,"briefSummary":372,"conditions":373,"keywords":380,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":387,"locationsCount":257},"100564678","dexa-bone-density-analysis-of-the-corehip-prosthesis-system-100564678","NCT06632301","DEXA Bone Density Analysis of the CoreHip® Prosthesis System","DEXA Bone Density Analysis to Analyze the Loading Concept of the CoreHip® Prosthesis","CODEX","Inclusion Criteria:\n\n* Unilateral hip osteoarthritis\n* Indication for CoreHip Standard hip stem according to preoperative planning\n* Written Informed Consent\n* Age 35-85 years\n* According to the assessment of the study doctor, the patient is therapy compliant and able to attend the follow-up visits\n\nExclusion Criteria:\n\n* Femoral neck fractures\n* Pregnancy\n* BMI \\> 35\n* History of femoral fracture or previous surgery on the same hip\n* Metabolic bone disease, use of steroids or other drugs affecting bone metabolism\n* Intraoperative bone cracks\n* Severe osteoarthritis of the contralateral hip\n* THA of the contralateral side or other event leading to restricted weight bearing during the study period","35 Years","85 Years",{"count":370,"type":21},40,[211],"The goal of this interventional post-market follow-up study is to evaluate radiological changes in the diaphyseal bone density (Gruen Zones 3 and 4) within 24 months postoperative in patients treated with CoreHip® primary cementless stem. The DEXA bone density analysis is used.",[374,375,376,377,378,379],"Primary Osteoarthritis","Cartilage Degeneration","Osteoarthritis, Hip","Inflammatory Arthritis","Osteonecrosis of Femoral Head","Traumatic Disorder",[381,382],"Total Hip Arthroplasty","DEXA Bone Density Analysis",{"date":354,"type":32},{"date":385,"type":21},"2026-06",{"date":64,"type":21},{"name":38,"class":39},{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":398,"conditions":399,"keywords":405,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":40},"100462536","evaluation-of-the-pheno4u-data-platform-in-patients-undergoing-total-knee-arthroplasty-100462536","NCT05302934","Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty","Prospective, Multinational Pilot Study for Evaluation of the PHENO4U Data Platform in Total Knee Arthroplasty Patients","Pheno4U Pilot","Inclusion Criteria:\n\n* Patient undergoing a total knee arthroplasty with a B. Braun knee implant system\n* Signed written informed consent\n* Patient's willingness \\& ability to use the \"BPMpathway\"sensor\n* Patient's willingness \\& ability to use the \"4Patient\" application\n\nExclusion Criteria:\n\n* Patient age \\\u003C 18 years\n* Patient not willing to participate at the further follow-up\n* Pregnancy\n* If intraoperatively an implant from a different manufacturer is used, the study patient has to be excluded from the study.",{"count":397,"type":21},600,"Prospective, multinational pilot study for evaluation of the Pheno4U data platform in Total Knee Arthroplasty (TKA) patients",[400,401,242,402,403,404],"Degenerative Osteoarthritis","Rheumatoid Arthritis","Chronic Instability of Knee","Stiffness of Knee","Deformity Knee",[406,407,408],"bi-condylar knee replacement","severe knee joint conditions","patient reported outcome",{"date":354,"type":32},{"date":411,"type":32},"2022-09-28",{"date":36,"type":21},{"name":38,"class":39},{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":209,"phases":424,"briefSummary":425,"conditions":426,"keywords":428,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":99},"100572787","ip-coated-revision-hip-implants-100572787","NCT06737809","IP-coated Revision Hip Implants","HIPrevision - A Randomized Multicenter Clinical Investigation of Antimicrobial IP-Coated Revision Hip Prostheses","HIPrevision","Inclusion Criteria:\n\n* Patients \\> 18 years\n* Patients indicated for unilateral cementless acetabular and hip stem revision due to chronic periprosthetic infection (according to EBJIS definition): single-stage or two-stage surgical procedure according to clinical standard at the clinical investigation site\n* According to the assessment of the clinical investigator, the subject is therapy compliant and able to attend the follow-up visits\n* ASA physical status I - III\n* Patient's signed written informed consent is available\n\nExclusion Criteria:\n\n* Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)\n* The investigational implant components (femoral and\u002For acetabular) are not suitable for the patient anatomy or bone defect\n* Patients who require plate osteosynthesis at the implantation site\n* Patients with an already implanted silver-coated device\n* Patients with immunodeficiency, i.e. patients currently receiving immunosuppressive therapy or patients with severe immunodeficiency requiring drug therapy\n* Patients currently undergoing cancer treatment, e.g. chemotherapy or radiation therapy\n* Severe soft tissue defects that require local or free flap procedure\n* Periprosthetic joint infections with evidence of fungal infection\n* Antibiotic suppression therapy\n* BMI \\> 40 kg\u002Fm2\n* Pregnancy, breast-feeding, or women of childbearing potential and not taking adequate contraceptive precautions\n* Known or patient reported hypersensitivity to silver or titanium\n* Patients held in a custodial setting\n* Patients in a relationship of dependence on the sponsor, the clinic or the investigator\n* Patients with contraindication for the investigational and comparator devices:\n* in case of secondary diseases influencing the function of the joint implant\n* in case of severe osteoporosis or osteomalacia\n* in case of poor bone quality and osseous malformations, diseases in the area of the implant fixation, which may primarily or subsequently affect the stability of the joint replacement anchorage\n* in case of non-regenerative bone conditions with lack of proximal femoral bone support and failure of defect union when use of prosthesis heads with neck length XXL is indicated",{"count":423,"type":21},268,[211],"The primary aim of the clinical investigation is to demonstrate the efficacy of a silver-based antimicrobial coating on hip implants in the reduction of periprosthetic infections in revision hip arthroplasty due to periprosthetic infection.",[427],"Peri-Prosthetic Joint Infection",[429,430,431,432,433,434],"arthroplasty","replacement","hip","anti-infective agent","silver","periprosthetic joint infection","2026-01-09",{"date":437,"type":32},"2026-01-12",{"date":439,"type":32},"2025-06-25",{"date":441,"type":21},"2028-06",{"name":38,"class":39},{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":209,"phases":453,"briefSummary":454,"conditions":455,"keywords":457,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":257},"100481360","ceramic-modular-dual-mobility-in-primary-total-hip-arthroplasty-tha-100481360","NCT05547984","Ceramic Modular Dual Mobility in Primary Total Hip Arthroplasty (THA)","A Randomized Controlled Trial Comparing Modular Dual Mobility Inserts With Ceramic Multilayer Coating Versus Standard Polyethylene Inserts for Primary Total Hip Arthroplasty (THA) in a Cementless Acetabular Cup","CeMoD-prime","Inclusion Criteria:\n\n* Primary coxarthrosis patients indicated for cementless total hip arthroplasty\n* Written informed patient consent\n\nExclusion Criteria:\n\n* Hip trauma or revision surgery\n* Rheumatoid or neurologic disease\n* BMI \\>35\n* Ongoing oncologic therapy\n* Preoperatively elevated Co or Cr serum levels \\>1.0 µg\u002FL\n* Patients with other joint implants, or anticipated need for another joint replacement surgery within the study period\n* Acetabular cup size \\\u003C52 expected\n* Patients not able to mentally or physically comply with the study demands and follow-up visits\n* Patients \\\u003C18 years at surgery\n* Pregnancy",{"count":452,"type":21},100,[211],"A randomized controlled trial comparing modular dual mobility inserts with ceramic multilayer coating versus standard polyethylene inserts for primary THA in a cementless acetabular cup",[456],"Coxarthrosis; Primary",[458,381],"Dual Mobility Cup","2025-12-15",{"date":461,"type":32},"2025-12-16",{"date":463,"type":32},"2022-11-21",{"date":465,"type":21},"2028-08",{"name":38,"class":39},{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":475,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":477,"conditions":478,"keywords":479,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":489,"locationsCount":40},"100589520","study-to-evaluate-the-performance-of-navigated-tka-with-orthopilot-pheno4u-tka-level-1-100589520","NCT06955481","Study to Evaluate the Performance of Navigated TKA With OrthoPilot® pheno4u TKA Level 1","Prospective, Single-arm, Multicenter Study to Evaluate the Performance of Navigated Total Knee Arthroplasty Using the OrthoPilot and the Software pheno4u TKA Level 1","TKA4U","Inclusion Criteria:\n\n* Indication for a TKA with the OrthoPilot® Navigation System with a Aesculap total knee endo-prosthesis\n* Written signed informed consent of patient\n* Willingness and mental ability to participate at the long-term follow-up examinations\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients \\\u003C 18 years or \\> 80 years\n* Patients unable to participate at the follow-up examination (physically, mentally)\n* Previous joint replacement at the index knee\n* ASA classification \\> 3 ( ASA I: A healthy patient without systemic diseases. ASA II: A patient with a mild systemic disease that is well controlled (e.g., well-controlled diabetes or hypertension). ASA III: A patient with a severe systemic disease that causes functional limitations (e.g., poorly controlled diabetes, COPD). ASA IV: A patient with a life-threatening systemic disease (e.g., severe heart failure, sepsis). ASA V: A dying patient who is not expected to survive without the operation. ASA VI: A deceased patient whose organs are being removed for donation.)","80 Years",{"count":160,"type":21},"The purpose of this PMCF study is to demonstrate the accuracy of navigation using the new pheno4uTKA Level 1 software for OrthoPilot Elite® and to evaluate its safety and performance.\n\nPatient-related outcome measures (PROM) will be acquired to investigate functional outcome and patient satisfaction.",[239,240,241,242],[480,481,482],"Navigation","Total Knee Arthroplasty","OrthoPilot","2025-11-14",{"date":485,"type":32},"2025-11-17",{"date":487,"type":32},"2025-10-07",{"date":441,"type":21},{"name":38,"class":39},""]